NCT01992432 (Brain fMRI-BC) is a clinical trial in Breast Cancer, sponsored by City of Hope Medical Center.

Who is sponsoring NCT01992432?

NCT01992432 is sponsored by City of Hope Medical Center.

What condition does NCT01992432 study?

NCT01992432 studies Breast Cancer.

Is NCT01992432 still recruiting?

NCT01992432 is currently active, enrolled. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT01992432: Brain fMRI-BC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)

Active, enrolled Last updated 28 January 2026

What this trial tests

trial in Breast Cancer in 49 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 September 2013

Primary endpoint
30 November 2026

30 November 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	49
Start date	30 September 2013
Primary completion	30 November 2026
Estimated completion	30 November 2026
Sites	2 locations across United States

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

City of Hope Medical Center

Who can join

65 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will use advanced MRI techniques to characterize the changes that occur to the structure and functionality of the brain in older breast cancer patients receiving adjuvant chemotherapy, and determine the relationship between the brain changes and severity of chemotherapy toxicity. Our results will be an early step towards identifying neuroimaging markers of aging, breast cancer and chemotherapy treatment, and will contribute to our understanding of the underlying pathophysiology of cognitive changes and chemotherapy toxicity in vulnerable, older adults with cancer. Furthermore, the work will lay the foundation for future, larger scale clinical studies of cognitive changes and chemotherapy toxicity in the aging cancer population.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study.
Chen BT, Sethi SK, Jin T, Patel SK, et al · · 2018 · cited 35× · PMID 29720224 · DOI 10.1186/s13058-018-0965-3
Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
Chen BT, Jin T, Patel SK, Ye N, et al · · 2018 · cited 33× · PMID 30088178 · DOI 10.1007/s10549-018-4911-y
Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
Chen BT, Jin T, Patel SK, Ye N, et al · · 2019 · cited 28× · PMID 30989462 · DOI 10.1007/s10549-019-05230-y
Effect of chemotherapy on default mode network connectivity in older women with breast cancer.
Chen BT, Chen Z, Patel SK, Rockne RC, et al · · 2022 · cited 11× · PMID 34019223 · DOI 10.1007/s11682-021-00475-y
Subcortical brain iron deposition and cognitive performance in older women with breast cancer receiving adjuvant chemotherapy: A pilot MRI study.
Chen BT, Ghassaban K, Jin T, Patel SK, et al · · 2018 · cited 11× · PMID 30076946 · DOI 10.1016/j.mri.2018.07.016

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01992432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01992432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing